Pet biotech Kindred Biosciences sets terms for $40 million IPO

By
A A A

Kindred Biosciences, a clinical-stage biotech developing pet therapeutics, announced terms for its IPO on Monday. The Burlingame, CA-based company plans to raise $40 million by offering 5.8 million shares at a price range of $6 to $8. At the midpoint of the proposed range, Kindred Biosciences would command a market value of $93 million.

Kindred Biosciences, which was founded in 2012, plans to list on the NASDAQ under the symbol KIN. Kindred Biosciences initially filed confidentially on October 2, 2013. BMO Capital Markets and Guggenheim Securities are the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: KIN

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

55,414,702
  • $15.38 ▼ 0.39%
38,503,210
  • $66.34 ▲ 2.26%
36,466,704
  • $8.36 ▼ 9.52%
35,253,294
  • $26.55 ▲ 1.34%
32,752,347
  • $6.55 ▲ 1.87%
31,778,001
  • $95.22 ▲ 0.19%
28,396,556
  • $51.49 ▼ 0.62%
23,800,987
  • $42.09 ▲ 0.97%
As of 7/11/2014, 04:03 PM